Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease.

Autor: Vrba L; The University of Arizona Cancer Center, Tucson, AZ, USA.; Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA., Futscher BW; The University of Arizona Cancer Center, Tucson, AZ, USA.; Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.; Precision Epigenomics Inc, Tucson, AZ, USA., Oshiro M; The University of Arizona Cancer Center, Tucson, AZ, USA., Watts GS; The University of Arizona Cancer Center, Tucson, AZ, USA.; Department of Medical Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA., Menashi E; Honor Health Hospital, Scottsdale, AZ, USA., Hu C; Dignity Health Chandler Regional Medical Center, Chandler, AZ, USA., Hammad H; The University of Arizona Cancer Center, Tucson, AZ, USA.; Division of Hematology/Oncology, Department of Medicine, University of Arizona Caner Center, Tucson, AZ, USA., Pennington DR; The University of Arizona Cancer Center, Tucson, AZ, USA.; Division of Hematology/Oncology, Department of Medicine, University of Arizona Caner Center, Tucson, AZ, USA., Golconda U; Department of Pathology, College of Medicine, University of Arizona, Tucson, AZ, USA., Gavini H; Division of Hematology/Oncology, Department of Medicine, University of Arizona Caner Center, Tucson, AZ, USA., Roe DJ; The University of Arizona Cancer Center, Tucson, AZ, USA., Shroff RT; The University of Arizona Cancer Center, Tucson, AZ, USA.; Division of Hematology/Oncology, Department of Medicine, University of Arizona Caner Center, Tucson, AZ, USA., Nelson MA; The University of Arizona Cancer Center, Tucson, AZ, USA. mnelson@pathology.arizona.edu.; Department of Pathology, College of Medicine, University of Arizona, Tucson, AZ, USA. mnelson@pathology.arizona.edu.; Precision Epigenomics Inc, Tucson, AZ, USA. mnelson@pathology.arizona.edu.
Jazyk: angličtina
Zdroj: Clinical epigenetics [Clin Epigenetics] 2022 Feb 22; Vol. 14 (1), pp. 28. Date of Electronic Publication: 2022 Feb 22.
DOI: 10.1186/s13148-022-01246-2
Abstrakt: We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje